肺耐药蛋白对常规化疗乳腺癌患者的预后影响

The influence of breast carcinoma prognosis after treated convention chemotherapies on LRP

目的探讨肺耐药蛋白对常规化疗后乳腺癌患者的预后影响。方法采用预后分析比较肺耐药蛋白阴阳性乳腺癌患者的生存期及分析对比有关临床病理因素之间的关系。结果在 152例乳腺癌组织中肺耐药蛋白阳性 122例 (80. 2％ )，淋巴结转移组阳性 62例 (88. 6％ )，无转移组阳性 60例 (73. 2％ )，两组间差异有显著性 (x2=5. 654， P< 0. 05)。单因素预后分析显示 LRP阳性组生存期明显低于阳性组 (x2=7. 092， P< 0. 01)。结论 (1)肺耐药蛋白可降低常规化疗后乳腺癌患者的生存期，可能与多药耐药有关。 (2)肺耐药蛋白阳性乳腺癌细胞更容易淋巴结转移。

Objective:To investigate The influence of breast carcinomas prognosis on LRP after treated convention chemotherapies.Methods:The survival terms in breast carcinomas patients with LRP of negativeness and positiveness were compared by using the prognostic analysis.Methods:It was compared to relate between LRP and clinicopathological parameters.Results:There were 122(80. 2％ )patients with LRP positiveness.In which,62(88. 6％ )were positive lymphoni nodes 60(73. 2％ )were negative lymphoni nodes.The positive ratio of LRP was clearly higher in the lymphoni nodes with metastasis than those in the lymphoni nodes without metastasis(x2=5. 654， P<0. 05).Univariate analysis demonstrated wores disease- free survival in patients with positive LRP cases than in those with negative LRP cases(x2=7. 092， P<0. 01).Conclusion:(1)The positive LRP cases can reduced the survival terms of breast cancer cases with convention chemotherapies.It s probably related to multidrug resistance.(2)The lRP positive cells in breast cancer are more apt to metastasize into axillary nodes.